Donor Cell Facilitation of Tolerance

供体细胞耐受性促进

基本信息

  • 批准号:
    7806783
  • 负责人:
  • 金额:
    $ 4.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-25 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term objective of the research program is to induce immune tolerance to allogeneic organ transplants such that immunosuppressive drugs are not required to maintain permanent graft acceptance. Previous studies in the program have shown that tolerance to heart allografts can be achieved using combined heart and bone marrow transplantation in wild-type MHC-mismatched murine hosts that have been conditioned with total lymphoid irradiation (TLI) and anti-thymocyte serum (ATS). The hosts become stable mixed chimeras without the development of graft versus host disease (GVHD). Tolerance induction and prevention of GVHD is dependent on host regulatory natural killer (NK) T cells that become the predominant residual T cell subset after TLI and ATS conditioning. Our recent studies show that tolerance and GVHD prevention is also dependent on the development of donor Treg cells and host Treg cells that are not NK T cells. A hypothesis that explains the results is that host NK T cells interact with host and donor APC's, and then augment/activate the non-NK Treg cells that provide alloantigen specificity for tolerance induction. Whereas the regulatory activity of the NK T cells is IL-4 dependent, that of the non-NK Treg cells is IL-4 and IL-10 dependent. The hypothesis will be tested by adding back purified NK T cells and non-NK Treg cells from wild-type, Treg deficient, and cytokine deficient (i.e. IL-4"'", IL-10"'") host and donor type mice to appropriate TLI/ATS conditioned hosts. The conditioned hosts will receive combined MHC-mismatched organ and bone marrow transplants, and graft acceptance and GVHD will be monitored. The phenotype and cytokine dependence of the non-NK Treg cells will be determined as well as the dependence of NK T cell activation on interaction with APC's. Our recent studies show that the NK T cells in wild type mice are far more resistant to apoptosis induced by TLI/ATS conditioning than conventional T cells. However, the differential resistance is lost in p53"'" mice and in Bcl-2 transgenic mice. We will determine whether the ability to induce tolerance and prevent GVHD is also lost in the latter genetically altered mice.
描述(由申请人提供):研究项目的长期目标是诱导对同种异体器官移植的免疫耐受,因此不需要免疫抑制药物来维持永久性移植物接受。该项目的先前研究表明,在已接受全淋巴照射(TLI)和抗胸腺细胞血清(ATS)处理的野生型MHC不匹配小鼠宿主中,使用心脏和骨髓联合移植可实现心脏同种异体移植耐受。宿主成为稳定的混合嵌合体,而不会发生移植物抗宿主病(GVHD)。GVHD的耐受性诱导和预防依赖于宿主调节性自然杀伤(NK)T细胞,其在TLI和ATS调节后成为主要的残余T细胞亚群。我们最近的研究表明,耐受性和GVHD预防也依赖于供体Treg细胞和非NK T细胞的宿主Treg细胞的发育。解释该结果的假设是宿主NK T细胞与宿主和供体APC相互作用,然后增强/激活非NK Treg细胞,其为耐受诱导提供同种抗原特异性。而NK T细胞的调节活性是IL-4依赖性的,非NK Treg细胞的调节活性是IL-4和IL-10依赖性的。将通过将来自野生型、Treg缺陷型和细胞因子缺陷型(即IL-4+、IL-10+)宿主和供体型小鼠的纯化的NK T细胞和非NK Treg细胞添加回适当的TLI/ATS条件化宿主中来测试该假设。条件化宿主将接受组合的MHC不匹配的器官和骨髓移植,并监测移植物接受性和GVHD。将确定非NK Treg细胞的表型和细胞因子依赖性以及NK T细胞活化对与APC相互作用的依赖性。我们最近的研究表明,野生型小鼠中的NK T细胞对TLI/ATS调节诱导的细胞凋亡的抗性远高于常规T细胞。然而,在p53+小鼠和Bcl-2转基因小鼠中,差异抗性丧失。我们将确定诱导耐受性和预防GVHD的能力是否也在后一种基因改变的小鼠中丧失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL STROBER其他文献

SAMUEL STROBER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL STROBER', 18)}}的其他基金

Radiotherapy as Immunotherapy of Tumors
放射治疗作为肿瘤的免疫治疗
  • 批准号:
    8521201
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Radiotherapy as Immunotherapy of Tumors
放射治疗作为肿瘤的免疫治疗
  • 批准号:
    8857115
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Radiotherapy as Immunotherapy of Tumors
放射治疗作为肿瘤的免疫治疗
  • 批准号:
    8370487
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Radiotherapy as Immunotherapy of Tumors
放射治疗作为肿瘤的免疫治疗
  • 批准号:
    8677809
  • 财政年份:
    2012
  • 资助金额:
    $ 4.8万
  • 项目类别:
Non-Myeloablative Host Conditioning that Protects Against GVHD
预防 GVHD 的非清髓性宿主调理
  • 批准号:
    8260363
  • 财政年份:
    2011
  • 资助金额:
    $ 4.8万
  • 项目类别:
Lupus Glomenulonephritis and NK T cells
狼疮性肾小球肾炎和 NK T 细胞
  • 批准号:
    7729007
  • 财政年份:
    2009
  • 资助金额:
    $ 4.8万
  • 项目类别:
Lupus Glomenulonephritis and NK T cells
狼疮性肾小球肾炎和 NK T 细胞
  • 批准号:
    8150359
  • 财政年份:
    2009
  • 资助金额:
    $ 4.8万
  • 项目类别:
Lupus Glomenulonephritis and NK T cells
狼疮性肾小球肾炎和 NK T 细胞
  • 批准号:
    8329719
  • 财政年份:
    2009
  • 资助金额:
    $ 4.8万
  • 项目类别:
Lupus Glomenulonephritis and NK T cells
狼疮性肾小球肾炎和 NK T 细胞
  • 批准号:
    8543713
  • 财政年份:
    2009
  • 资助金额:
    $ 4.8万
  • 项目类别:
Lupus Glomenulonephritis and NK T cells
狼疮性肾小球肾炎和 NK T 细胞
  • 批准号:
    7916783
  • 财政年份:
    2009
  • 资助金额:
    $ 4.8万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了